The tumor‑infiltrating lymphocyte (TIL) field has gained momentum with recent regulatory approvals, but experts say operational, manufacturing and access challenges persist. The review highlights that inspection‑ready manufacturing, supply‑chain resilience and scalable quality systems are necessary for wider TIL adoption beyond specialized centers. TILs require complex cell‑therapy workflows and robust logistics; sponsors that standardize processes, document change histories and invest in traceable digital systems will better withstand regulatory scrutiny and scale. The piece frames TILs as clinically promising but operationally demanding for broad commercialization.